Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as potentially useful for the treatment of epilepsy, schizophrenia, autism, cancer, mood disorder, sepsis, Alzheimer’s disease and vascular disorders, among others.
Less than two years on from its formation, central nervous system diseases specialist Accure Therapeutics SL has landed a $1 billion-plus agreement to out-license the lead program ACT-01, a first-in-class molecule with neuroprotective properties that is in a phase IIa study in acute optic neuritis. Taking on ACT-01 is ophthalmology specialist Oculis SA, which once it has positive data from the phase IIa, intends to expand to broader indications, including glaucoma and geographic atrophy.
